The first AI-driven MRI solution for safer Alzheimer’s treatment

On November 7th, 2024, the U.S. Food and Drug Administration (FDA) granted icometrix clearance for icobrain aria, the first and only AI software approved for detecting, measuring, and grading amyloid-related imaging abnormalities (ARIA), a potentially harmful side effect of new amyloid-targeting therapies. A large study, needed for FDA clearance, demonstrated that the use of icobrain aria significantly increases the accuracy of ARIA assessments by radiologists, hence allowing for safer use of new amyloid-beta targeting therapies for Alzheimer’s disease patients.

This FDA clearance is a big step forward in Alzheimer’s care, demonstrating how technology can help bring safe and effective treatments to more people. With icobrain aria, physicians now have a powerful tool that helps them make informed treatment decisions, ensuring that patients receive the right care at the right time. This is a clear example of how advanced technology can make a difference in healthcare, supporting doctors and making important new therapies more widely accessible.

The FDA’s nod for icobrain aria comes at a time when much-needed new Alzheimer’s treatments are reshaping care options in the United States. The first breakthrough in Alzheimer’s disease treatment was in 2021 when aducanumab (Aduhelm) became the first FDA-approved drug intended to slow Alzheimer’s progression by reducing amyloid plaques in the brain.

> "We strive to advance both access and operational efficiency through technology to ensure timely and effective care for our patients. In our commitment to providing cutting-edge therapeutic interventions to our community, we are proud to collaborate with icometrix to deliver highly innovative diagnostics and monitoring for patients receiving these emerging therapies," said Lee Williams, Chief Executive Officer of Dent Neurologic Institute.

> Dr. Laszlo Mechtler, Chief Medical Officer at DENT Neurologic, states, “With the aging American population, Alzheimer’s disease and dementias are becoming more frequent, causing significant morbidity and cost to our healthcare system. At the DENT, we have developed a center of excellence treating memory disorders/dementia and have partnered with icometrix’s groundbreaking tool in the evaluation of MRI changes in patients with cognitive disabilities/dementia. This is especially important in the quest for cures and treatment. In 2024, there are 171 ongoing clinical trials on 134 drugs being tested in Alzheimer’s disease. The Dent Neurologic Institute will be on the forefront of this cutting-edge research.”